← Every company
Exelixis Inc Patents
What Exelixis Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
EXEL on carbonthat →Filings on file
54
Granted
3
Still pending
51
Filed under
2 names
54 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| ANTIBODY-DRUG CONJUGATES AND METHODS OF THEIR USEFiled as EXELIXIS, INC.2026-03-20AMY PETERSON | pending |
| 5T4 ANTIBODY DRUG CONJUGATES AND METHODS OF THEIR USEFiled as EXELIXIS, INC.2026-03-06AMY PETERSON | pending |
| Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such CompoundsA61P 35/00, A61K 31/47, C07D 215/22, C07D 215/233Filed as Exelixis, Inc.2026-02-11Jo Ann Wilson | pending |
| FUSED PYRAZOLE DERIVATIVES AS USP1 INHIBITORSFiled as EXELIXIS, INC.2026-01-06Chandrasekhar Abbineni | pending |
| PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDSFiled as Exelixis, Inc.2025-12-12Jo Ann Wilson | pending |
| DLL3 ANTIBODY-DRUG CONJUGATES AND USES THEREOFFiled as EXELIXIS, INC.2025-09-16Kathleen GOGAS | pending |
| C-Met Modulator Pharmaceutical CompositionsA61K 31/47, A61K 9/00, A61K 9/2004, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2031, A61K 9/2054, A61K 9/2095, A61K 9/28, A61K 9/2833, A61K 9/2866, A61K 9/2893, A61K 31/00, A61K 31/33, A61K 31/395, A61K 31/435, A61K 45/06Filed as Exelixis, Inc.2025-08-20Jo Ann Wilson | pending |
| METHODS OF USE OF AGENTS THAT BIND TO NKG2A AND PD-L1Filed as EXELIXIS, INC.2025-07-30SEEMA KANTAK | pending |
| AGENTS THAT BIND TO NKG2A AND PD-L1 AND USES THEREOFA61P 29/00, C07K 16/2803, C07K 16/2827, A61P 37/00, A61P 37/04, A61P 35/00, A61K2039/505, C07K2317/31, C07K2317/32, C07K2317/33, C07K2317/34, C07K2317/515, C07K2317/522, C07K2317/524, C07K2317/526, C07K2317/565, C07K2317/567, C07K2317/73, C07K2317/75, C07K2317/76, C07K2317/92Filed as EXELIXIS, INC.2025-07-25Bonnie HAMMER | pending |
| NKG2A BINDING AGENTS AND USES THEREOFA61P 35/00, C07K 16/2803, A61K 47/6849, A61P 37/00, A61K2039/505, C07K2317/24, C07K2317/30, C07K2317/31, C07K2317/34, C07K2317/565, C07K2317/567, C07K2317/76, C07K2317/92Filed as EXELIXIS, INC.2025-07-25Bonnie HAMMER | pending |
| COMPOUNDS THAT INHIBIT PKMYT1A61K 31/437, C07D 471/04, A61K 31/404, A61K 31/416, A61K 31/4184, A61K 31/4192, A61K 31/444, C07D 209/42, C07D 231/56, C07D 235/06, C07D 235/08, C07D 235/10, C07D 249/18, C07D 401/04Filed as Exelixis, Inc.2025-06-18Wei Xu | pending |
| Compounds that Inhibit PKMYT1C07D 401/04, C07D 471/04, A61P 35/00, A61K 31/4375, A61K 31/444, A61K 31/47, A61K 31/4709, A61K 31/472, A61K 31/498, A61K 31/4985, A61K 31/501, A61K 31/506, A61K 31/517, A61K 31/519, A61K 31/5377, C07D 215/48, C07D 215/50, C07D 217/02, C07D 217/24, C07D 241/42, C07D 241/44, C07D 403/04, C07D 413/04, C07D 417/04, C07D 487/04, C07D 491/107, C07D 519/00Filed as Exelixis, Inc.2025-05-23Wei XU | pending |
| PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDSA61P 35/00, A61K 31/47, C07D 215/22, C07D 215/233Filed as Exelixis, Inc.2025-05-08Jo Ann Wilson | pending |
| SOMATOSTATIN RECEPTOR 2 AGONISTS AND USES THEREOFA61K 31/4745, C07D 213/78, C07D 215/233, A61P 3/10, A61K 31/4436, A61K 31/444, A61K 31/47, A61K 31/4709, A61K 31/496, A61K 31/519, C07D 213/74, C07D 215/12, C07D 401/04, C07D 401/14, C07D 471/04, C07D 471/10, C07D 471/14, C07D 471/18, C07D 471/22, C07D 487/10, C07D 491/048, C07D 491/052, C07D 491/08, C07D 495/04, C07D 498/18, C07D 513/16, C07D 513/22Filed as Exelixis, Inc.2025-04-25Dongcheng DAI | pending |
| 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORSC07D 471/04, A61P 35/00, A61K 31/437, A61K 31/444, A61K 31/506Filed as EXELIXIS, INC.2025-04-18Chandrasekhar ABBINENI | pending |
| ANTIBODY-DRUG CONJUGATES AND METHODS OF THEIR USEFiled as EXELIXIS, INC.2025-03-21Amy PETERSON | pending |
| 5T4 ANTIBODY DRUG CONJUGATES AND METHODS OF THEIR USEFiled as EXELIXIS, INC.2025-03-07Amy PETERSON | pending |
| Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerC07D 215/22, C07D 215/233, A61K 31/47, A61P 43/00, A61P 25/00, A61P 5/14, A61P 35/00, C07B2200/13Filed as Exelixis, Inc.2025-03-04Adrian St. Clair Brown | pending |
| TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND USES THEREOFA61K 47/6849, A61K 47/6889, A61K 47/68037, C07K 16/36Filed as EXELIXIS, INC.2025-02-25Robyn M. BARFIELD | pending |
| METHODS FOR PROTEIN PURIFICATIONFiled as EXELIXIS, INC.2025-02-19LARRY JOE ANDERSON | pending |
| C-MET MODULATOR PHARMACEUTICAL COMPOSITIONSA61K 31/47, A61K 9/00, A61K 9/2004, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2031, A61K 9/2054, A61K 9/2095, A61K 9/28, A61K 9/2833, A61K 9/2866, A61K 9/2893, A61K 31/00, A61K 31/33, A61K 31/395, A61K 31/435, A61K 45/06Filed as Exelixis, Inc.2025-01-02Jo Ann Wilson | pending |
| MALATE SALT OF N-(4-{[6,7-BIS(METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCERA61K 31/47, C07D 215/22, C07D 215/233, A61P 43/00, A61P 25/00, A61P 5/14, A61P 35/00, C07B2200/13Filed as Exelixis, Inc.2024-11-25Adrian St. Clair Brown | 12275706 |
| COMPOUNDS THAT INHIBIT POLO-LIKE KINASE 4Filed as EXELIXIS, INC.2024-11-19SANJAY BHATTARAI | pending |
| 5T4 ANTIBODY DRUG CONJUGATES AND METHODS OF THEIR USEFiled as EXELIXIS, INC.2024-11-14AMY PETERSON | pending |
| COMPOUNDS THAT INHIBIT POLO-LIKE KINASE 4Filed as Exelixis, Inc.2024-11-08Brian Sherer | pending |
| METHODS FOR TREATING CANCER USING COMPOUNDS THAT INHIBIT PKMYT1Filed as EXELIXIS, INC.2024-11-07DANA GWINN | pending |
| 5T4 BINDING AGENTS AND USES THEREOFC07K 16/30, A61P 35/00, A61K2039/505, C07K2317/21, C07K2317/30, C07K2317/33, C07K2317/52, C07K2317/55, C07K2317/56, C07K2317/565, C07K2317/567, C07K2317/77, C07K2317/92, C07K2317/94, C07K2319/00Filed as EXELIXIS, INC.2024-11-06Bonnie HAMMER | pending |
| 5T4 ANTIBODY-DRUG CONJUGATES AND USES THEREOFA61K 47/6851, A61K 47/68031, C07K 16/30, A61K 47/6889, A61P 35/00, A61K 47/68033, A61K2039/505, C07K2317/21, C07K2317/33, C07K2317/34, C07K2317/55, C07K2317/92, C07K2317/94Filed as EXELIXIS, INC.2024-11-06Seema KANTAK | pending |
| METHODS FOR TREATING CANCER USING COMPOUNDS THAT INHIBIT PKMYT1Filed as Exelixis, Inc.2024-10-04Dana GWINN | pending |
| Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such CompoundsA61P 35/00, A61K 31/47, C07D 215/22, C07D 215/233Filed as Exelixis, Inc.2024-09-27Jo Ann Wilson | pending |
| ILT2 BINDING AGENTS AND USES THEREOFFiled as EXELIXIS, INC.2024-08-30RAMESH BALIGA | pending |
| ANTI-ROR ANTIBODY CONSTRUCTSA61P 35/00, C07K 16/2803, A61K 45/06, A61K2039/505, C07K 16/2809, C07K 16/2818, C07K 16/2878, C07K 16/468, C07K2317/24, C07K2317/31, C07K2317/35, C07K2317/522, C07K2317/524, C07K2317/526, C07K2317/55, C07K2317/77, C07K2317/92, C07K2317/94Filed as EXELIXIS, INC.2024-08-12Lucas BAILEY | pending |
| MULTISPECIFIC BINDING AGENTS AND USES THEREOFC07K 16/2803, C07K 16/2827, A61K 47/6849, A61K 47/6879, A61P 35/00, A61K2039/505, A61K2039/545, C07K2317/31, C07K2317/73, C07K2317/732, C07K2317/76, C07K2317/92Filed as EXELIXIS, INC.2024-08-07Bryan GLASER | pending |
| FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORSC07D 471/04, A61P 35/02, A61P 35/00, C07D 475/00, C07D 487/04, C07D 498/04, C07D 519/00Filed as Exelixis, Inc.2024-07-31Chandrasekhar ABBINENI | pending |
| METHODS OF USE OF AGENTS THAT BIND TO NKG2A AND PD-L1Filed as EXELIXIS, INC.2024-07-31Seema KANTAK | pending |
| TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR 1 (ROR1) ANTIBODY-DRUG CONJUGATES AND USES THEREOFFiled as EXELIXIS, INC.2024-07-19KATHLEEN GOGAS | pending |
| INTERLEUKIN-13 RECEPTOR SUBUNIT ALPHA-2 BINDING AGENTS AND USES THEREOFFiled as EXELIXIS, INC.2024-07-19RAMESH BALIGA | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATESA61K 47/6849, A61K 47/68031, A61K 47/6889, A61K 47/6851, A61P 35/00, A61K 9/0019, A61K 9/19, A61K 47/183, A61K 47/22, A61K 47/26Filed as EXELIXIS, INC.2024-07-19Mark REYNOLDS | pending |
| ACTIVATABLE TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR (ROR) ANTIBODY-DRUG CONJUGATES AND USES THEREOFFiled as EXELIXIS, INC.2024-07-19MAXINE BAUZON | pending |
| ACTIVATABLE ROR BINDING AGENTS AND USES THEREOFFiled as EXELIXIS, INC.2024-07-19FANGYONG DU | pending |
| INTERLEUKIN-13 RECEPTOR SUBUNIT ALPHA-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOFFiled as EXELIXIS, INC.2024-07-19PENELOPE M. DRAKE | pending |
| FUSED PYRAZOLE DERIVATIVES AS USP1 INHIBITORSFiled as EXELIXIS, INC.2024-07-02CHANDRASEKHAR ABBINENI | pending |
| CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITORC07D 215/48, A61P 35/00Filed as Exelixis, Inc.2024-06-21Kirsten PHIZACKERLEY | pending |
| METHOD OF TREATING CANCER AND BONE CANCER PAINA61K 31/47, A61K 31/517, C07D 215/233, A61P 19/00, A61P 25/04, A61P 35/04, A61P 35/00, A61K 31/536Filed as Exelixis, Inc.2024-06-04Gisela Schwab | pending |
| MEK INHIBITORS AND METHODS OF THEIR USEA61K 31/397, C07D 205/04, C07D 205/06, C07D 403/06, A61P 17/06, A61P 43/00, A61P 35/02, A61P 17/02, A61P 35/00, C07D 401/04, C07D 401/06, C07D 401/12, C07D 401/14, C07D 403/04, C07D 403/12, C07D 405/12, C07D 409/06, C07D 409/12, C07D 413/12, C07D 413/14, C07D 417/12, C07D 471/04Filed as Exelixis, Inc.2024-05-23Naing Aay | pending |
| Liquid Dosage Forms to Treat CancerA61K 31/47, A61P 35/00, A61K 9/0053Filed as Exelixis, Inc.2024-05-10Khalid Shah | pending |
| CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITORC07D 215/48, A61P 35/00, A61K 31/47, C07B2200/13Filed as Exelixis, Inc.2024-05-07Frenel DeMorin | 12679809 |
| COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERSC07D 215/48, A61K 31/47Filed as Exelixis, Inc.2024-05-02Khalid SHAH | pending |
| METABOLITES OF N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDEC07C 233/60, C07D 215/22, C07C2601/02, A61P 35/00, C07C 305/24, C07D 215/60, G01N 33/487, G01N2570/00Filed as Exelixis, Inc.2024-04-22Dana T. Aftab | pending |
| METHODS FOR TREATING CANCER USING COMPOUNDS THAT INHIBIT PKMYT1Filed as Exelixis, Inc.2024-04-05Dana Gwinn | pending |
| AMHRII ANTIBODY-DRUG CONJUGATES AND USES THEREOFFiled as EXELIXIS, INC.2024-03-28YUTAKA MATSUDA | pending |
| Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancerA61K 31/47, C07D 215/22, C07D 215/233, A61P 43/00, A61P 25/00, A61P 5/14, A61P 35/00, C07B2200/13Filed as Exelixis, Inc.2024-03-21Adrian St. Clair Brown | pending |
| DLL3 ANTIBODY-DRUG CONJUGATES AND USES THEREOFFiled as EXELIXIS, INC.2024-03-21KATHLEEN GOGAS | pending |
| PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDSA61P 35/00, A61K 31/47, C07D 215/22, C07D 215/233Filed as Exelixis, Inc.2024-02-08Jo Ann Wilson | 12128039 |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on EXEL
Company overviewEverything on EXEL in one place, with the price.SEC filingsWhat EXEL's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat EXEL's own officers and directors buy and sell.Executive payWhat EXEL awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in EXEL.Funds holding itWhich funds and ETFs hold EXEL, and how big a bet.LobbyingWhat EXEL spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on EXEL's account, and who they worked for.